Ailec Estrada
Nurse Practitioner · Pinecrest, FLNPI 1508196684
Payments from drug & device makers
Across 112 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$424
- Lilly USA, LLC$305
- Tandem Diabetes Care, Inc.$187
- Corcept Therapeutics$162
- Abbott$122
- Sanofi-aventis U.S. LLC$118
- plus $1000 from 22 others
What the payments were for
- Food & beverage$2,318100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $424 |
| Lilly USA, LLC | 19 | $305 |
| Tandem Diabetes Care, Inc. | 7 | $187 |
| Corcept Therapeutics | 7 | $162 |
| Abbott | 6 | $122 |
| Sanofi-aventis U.S. LLC | 5 | $118 |
| Dexcom, Inc. | 6 | $113 |
| Sequel Med Tech, LLC | 3 | $107 |
| BETA Bionics, Inc. | 5 | $96 |
| Boehringer Ingelheim | 4 | $94 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| Insulet Corporation | 3 | $63 |
| AbbVie | 3 | $45 |
| GSK | 2 | $43 |
| Novartis | 2 | $42 |
| Astellas Pharma US Inc | 2 | $42 |
| Bayer | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Averitas Pharma Inc. | 1 | $26 |
| IBSA Pharma Inc. | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $23 |
| Osprey Medical Inc | 1 | $22 |
| Mannkind Corporation | 1 | $20 |
| Medtronic | 1 | $19 |
| Abiomed | 1 | $19 |
| RGH Enterprises LLC | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
How this compares
$2,318 in reported general payments places this provider in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 205 | $250,459 |
| JardianceEmpagliflozin | 145 | $172,249 |
| MounjaroTirzepatide | 107 | $132,003 |
| Tresiba Flextouch U-100Insulin Degludec | 202 | $118,585 |
| TrulicityDulaglutide | 76 | $86,873 |
| FarxigaDapagliflozin Propanediol | 92 | $80,428 |
| RybelsusSemaglutide | 38 | $50,992 |
| JanuviaSitagliptin Phosphate | 42 | $39,322 |
| TradjentaLinagliptin | 37 | $37,160 |
| ProliaDenosumab | 20 | $33,438 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 19 | $26,379 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 181 | $20,903 |
| Novolog FlexpenInsulin Aspart | 104 | $19,797 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 196 | $15,524 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $14,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $424 | $310,892271 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $305 | $220,800197 claims |
| Boehringer IngelheimJardiance, Tradjenta | $94 | $209,409182 claims |
| AbbVieSynthroid | $45 | $12,748153 claims |
| IBSA Pharma Inc.Tirosint | $25 | $3,65317 claims |
| Sanofi-aventis U.S. LLCLantus | $118 | $2,06915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,290 nurse practitioner providers in Florida.
Other nurse practitioner in Pinecrest
- Iani SilveiraPinecrest$132K
- Jolanta BaginskiClearwater$494K
- Adissa PerezWinter Park$370K
- April WessonTampa$342K
- Margarita FernandezMiami$311K
- Stephanie SimmermanNaples$283K
- Claudette WalkerPonte Vedra Beach$271K
- Lisa NodzonTampa$246K
- Ashima BahlTampa$226K
- Maya BloombergMiami$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.